Non-estrogen conventional and phytochemical treatments for vasomotor symptoms: What needs to be known for practice

Climacteric

Volumn 15, Issue 2, 2012, Pages 115-124

  Villaseca, P ^a  

^a PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

Author keywords

Black Cohosh; Clonidine; Gabapentin; hot flushes; isoflavones; non estrogen conventional treatment; phytochemical treatment; phytoestrogens; review; Snri; SSRI; vasomotor symptoms

Indexed keywords

CIMICIFUGA RACEMOSA EXTRACT; CITALOPRAM; CLONIDINE; CYTOCHROME P450; DESVENLAFAXINE; DULOXETINE; ENDOXIFEN; ESCITALOPRAM; ESTROGEN; ESTROGEN RECEPTOR BETA; FLUOXETINE; GABAPENTIN; ISOFLAVONE; LETROZOLE; PAROXETINE; PHYTOESTROGEN; PLACEBO; PREGABALIN; RED CLOVER EXTRACT; SERTRALINE; TAMOXIFEN; VENLAFAXINE;

ANXIETY; BINDING AFFINITY; BIOAVAILABILITY; BREAST CANCER; CHEMICAL STRUCTURE; CIMICIFUGA RACEMOSA; CLINICAL PRACTICE; CLOVER; CONCENTRATION LOSS; CONSTIPATION; DEMETHYLATION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG ANTAGONISM; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERANCE; ENDOMETRIUM HYPERPLASIA; FATIGUE; FOLLOW UP; HOT FLUSH; HUMAN; HYDROXYLATION; HYPOTENSION; HYPOTHALAMUS; INSOMNIA; LONG TERM CARE; MAJOR DEPRESSION; MENOPAUSE; NAUSEA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHYTOCHEMISTRY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RED CLOVER; REVIEW; SIDE EFFECT; SOMNOLENCE; SOYBEAN; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT RESPONSE; UNSTEADINESS; VASOMOTOR DISORDER; XEROSTOMIA;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; AMINES; ANTICONVULSANTS; CIMICIFUGA; CLONIDINE; CYCLOHEXANECARBOXYLIC ACIDS; FEMALE; GAMMA-AMINOBUTYRIC ACID; HOT FLASHES; HUMANS; MENOPAUSE; PHYTOESTROGENS; PHYTOTHERAPY; PLANT EXTRACTS; SEROTONIN UPTAKE INHIBITORS; SWEATING; VASOMOTOR SYSTEM;

EID: 84858436635     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2011.624214     Document Type: Review

References (109)

1. Palacios S, Henderson VW, Siseles N, et al. Age of menopause and impact of climacteric symptoms by geographical region. Climacteric 2010;13:419-28
2. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77 (Pubitemid 46556472)
3. Hunter MS, Grunfeld EA, Mittal S, et al. Menopausal symptoms in women with breast cancer: prevalence and treatment preferences. Psychooncology 2004;13:769-78 (Pubitemid 39549576)
4. Newton KM, Reed SD, LaCroix AZ, et al. Treatment of vasomo-tor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med 2006;145:869-79 (Pubitemid 351639962)
5. MacLennan A, Broadbent JL, Lester S, et al. Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;18:CD002978
6. http://nccam.nih.gov/health/whatiscam/, National Institute of Health. National Center for Complementary and Alternative Medicine
7. Clayden JR, Bell JW, Pollard P. Menopausal flushing: double blind trial of non-hormonal medication. BMJ 1974;1:409-12
8. Goldberg RM, Loprinzi CL, O'Fallon JR, et al. Transdermal clonidine for ameliorating tamoxifen-induced hot flashes. J Clin Oncol 1994;12:155-8 (Pubitemid 24020635)
9. Pandya KJ, Raubertas RF, Flynn PJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. Ann Intern Med 2000;132:788-93 (Pubitemid 30317793)
10. Guttuso TJ Jr. Gabapentin's effects on hot flashes and hypothermia. Neurology 2000;54:2161-3 (Pubitemid 30397222)
11. Guttuso T Jr, Kurlan R, McDermott M P, et al. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. Obstet Gynecol 2003;101:337-45 (Pubitemid 36170136)
12. Pandya KJ, Morrow GR, Roscoe JA, et al. Gabapentin for hot flashes in 420 women with breast cancer: a randomised double-blind placebo-controlled trial. Lancet 2005;366: 818-24 (Pubitemid 41557381)
13. Toulis KA, Tzellos T, Kouvelas D, et al. Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis. Clin Ther 2009;31:221-35
14. Butt DA, Lock M, Lewis JE, et al. Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. Menopause 2008;15:310-18 (Pubitemid 351354993)
15. Dogukan A, Aygen B, Berilgen MS, et al. Gabapentin-induced coma in a patient with renal failure. Hemodial Int 2006;10: 168-9
16. Lasso-de-la-Vega MC, Zapater P, Such J, et al. Gabapentin-associated hepatotoxicity. Am J Gastroenterol 2001;96:3460-2
17. Loprinzi CL, Qin R, Balcueva EP, et al. Phase III, randomized, double-blind, placebo-controlled evaluation of pregabalin for alleviating hot flashes, N07C1. J Clin Oncol 2010;28:641-7
18. Stearns V, Ullmer L, López JF, et al. Hot flushes. Lancet 2002;360:1851-61 (Pubitemid 35449427)
19. Loprinzi CL, Sloan JA, Perez EA, et al. Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 2002;20: 1578-83 (Pubitemid 34260538)
20. Barton DL, LaVasseur BI, Sloan JA, et al. Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9. J Clin Oncol 2010;28:3278-83
21. Suvanto-Luukkonen E, Koivunen R, Sundström H, et al. Citalo-pram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. Menopause 2005;12:18-26 (Pubitemid 40204889)
22. Freeman EW, Guthrie KA, Caan B, et al. Efficacy of escitalopram for hot flashes in healthy menopausal women: a randomized controlled study. JAMA 2011;305:267-74
23. Wu MF, Hilsenbeck SG, Tham YL, et al. The efficacy of sertraline for controlling hot flashes in women with or at high risk of developing breast cancer. Breast Cancer Res Treat 2009;118:369-75
24. Kerwin JP, Gordon PR, Senf JH. The variable response of women with menopausal hot flashes when treated with sertraline. Menopause 2007;14:820-2
25. Grady D, Cohen B, Tice J, et al. Ineffectiveness of sertraline for treatment of menopausal hot flushes: a randomized controlled trial. Obstet Gynecol 2007;109:823-30 (Pubitemid 46559068)
26. Gordon PR, Kerwin JP, Boesen KG, et al. Setraline to treat hot flashes: a randomized controlled, double-blind, crossover trial in a general population. Menopause 2006;13:546-8
27. Kimmick GG, Lovato J, McQuellon R, et al. Randomized, double-blind, placebo-controlled, crossover study of sertraline (Zoloft) for the treatment of hot flashes in women with early stage breast cancer taking tamoxifen. Breast J 2006;12:114-22
28. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. JAMA 2003;289:2827-34 (Pubitemid 37430118)
29. Stearns V, Slack R, Greep N, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. J Clin Oncol 2005;23:6919-30
30. van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993;24:203-20 (Pubitemid 23094387)
31. Stearns V, Johnson MD, Rae JM, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin uptake inhibitor paroxetine. J Natl Cancer Inst 2003;95:1758-64 (Pubitemid 38008898)
32. Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepres-sant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:30-9
33. Kelly CM, Juurlink DN, Gomes T, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ 2010:340: c693
34. Loprinzi CL, Kugler JW, Sloan JA, et al. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:2059-63 (Pubitemid 32009821)
35. Evans ML, Pritts E, Vittinghoff E, et al. Management of post-menopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. Obstet Gynecol 2005;105:161-6 (Pubitemid 40189927)
36. Ladd CO, Newport DJ, Ragan KA, et al. Venlafaxine in the treatment of depressive and vasomotor symptoms in women with perimenopausal depression. Depress Anxiety 2005;22: 94-7 (Pubitemid 41598045)
37. Carpenter JS, Storniolo AM, Johns S, et al. Randomized, double-blind, placebo-controlled crossover trials of venlafaxine for hot flashes after breast cancer. Oncologist 2007;12:124-35 (Pubitemid 46150798)
38. Nichols AI, Tourian KA, Tse S Y, et al. Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor. Expert Opin Drug Metab Toxicol 2010;6:1565-74
39. Speroff L, Gass M, Constantine G, Olivier S, for the Study 315 Investigators. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. Obstet Gynecol 2008;111:77-87
40. Archer D, Dupont CM, Constantine GD, Pickar JH, Olivier S, for the Study 319 Investigators. Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety respectively. Am J Obstet Gynecol 2009;200:238. e1-e10
41. Nichols AI, Richards LS, Behrle JA, et al. The pharmacokinetics and safety of desvenlafaxine in subjects with chronic renal impairment. Int J Clin Pharmacol Therapeutics 2011;49:3-13
42. Joffe H, Soares CN, Petrillo L F, et al. Treatment of depression and menopause-related symptoms with the serotonin-norepine-phrine reuptake inhibitor duloxetine. J Clin Psychiatry 2007;68: 943-50 (Pubitemid 47015497)
43. Cheema D, Coomarasamy A, El-Toukhy T. Non-hormonal therapy of post-menopausal vasomotor symptoms: a structured evidence-based review. Arch Gynecol Obstet 2007;276:463-9 (Pubitemid 47415761)
44. Rada G, Daniel Capurro D, Tomas Pantoja T, et al. Non-hormonal interventions for hot flushes in women with a history of breast cancer. Cochrane Database Systematic Rev 2010, Issue 9. Art. No.: CD004923
45. RD Congress (1994)
46. Manach C, Hubert J, Llorach R, et al. The complex links between dietary phytochemicals and human health deciphered by meta-bolomics. Mol Nutr Food Res 2009;53:1303-15
47. http://www.efsa.europa.eu/
48. Sakata K, Ohyanagi H, Hiroya Nobori H, et al. Soybean proteome database: a data resource for plant differential omics. J Proteome Res 2009;8:3539-48
49. Booth NL, Overk CR, Yao P, et al. The chemical and biological profile of a red clover (Trifolium pratense) phase II clinical extract. J Altern Complement Med 2006;12:133-9
50. Atkinson C, Frankenfeld CL, Lampe JW. Gut bacterial metabolism of the soy isoflavone daidzein: exploring the relevance to human health. Exp Biol Med 2005;230:155-70 (Pubitemid 40293689)
51. Brandon DL, Bates AH, Friedman M. ELISA analysis of soybean trypsin inhibitors in processed foods. Adv Exp Med Biol 1991; 289:321-37
52. Speroni Aguirre FJ, Milesi V, Añón MC. Effect of extraction and precipitation conditions during soybean protein isolate production on the genistein series content. J Am Oil Chem Soc 2007; 84:305-14 (Pubitemid 46931884)
53. Kim SH, Jung WS, Ahn JK, et al. Analysis of isoflavone concentration and composition in soybean Glycine max (L.) seeds between the cropping year and storage for 3 years. Eur Food Res Tech 2007;220:207-14 (Pubitemid 40536300)
54. Booth NL, Overk CR, Yao P, et al. Seasonal variation of red clover (Trifolium pratense L., Fabaceae) isoflavones and estro-genic activity. J Agric Food Chem 2006;54:1277-82 (Pubitemid 43378982)
55. Lampe J W, Chang JL. Interindividual differences in phytochemi-cal metabolism and disposition. Semin Cancer Biol 2007;17: 347-53 (Pubitemid 47369172)
56. Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr 2002;132:3577-84 (Pubitemid 35435031)
57. Lampe J, Karr S, Hutchins A, et al. Urinary equol excretion with a soy challenge: influence of habitual diet. Proc Soc Exp Biol Med 1998;217:335-9
58. Tew BY, Xu X, Huei-Ju W, et al. A diet high in wheat fiber decreases the bioavailability of soybean isoflavones in a single meal fed to women. J Nutr 1996;126:871-7 (Pubitemid 26100957)
59. Kuiper GGJM, Lemmen JG, Carlsson B, et al. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor β. Endocrinology 1998;139:4252-63 (Pubitemid 28513713)
60. Pfitscher A, Reiter E, Jungbauer A. Receptor binding and trans-activation activities of red clover isoflavones and their metabolites. J Steroid Biochem Mol Biol 2008;112:87-94
61. Koehler K F, Helguero LA, Haldosén LA, et al. Reflections on the discovery and significance of estrogen receptor β. Endocr Rev 2005;26:465-78 (Pubitemid 40691301)
62. Nilsson S, Gustafsson J-Å. Estrogen receptors: therapies targeted to receptor subtypes. Clin Pharmacol Therap 2011;89:44-55
63. Routledge EJ, White R, Parker MG, et al. Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor (ER) alpha and ER beta. J Biol Chem 2000;275:35986-93
64. Beck E, Unterrieder E, Krenn L, et al. Comparison of hormonal activity (estrogen, androgen and progestin) of standardized plant extracts for large scale use in hormone replacement therapy. J Steroid Biochem Mol Biol 2003;84:259-68 (Pubitemid 36514843)
65. Dechaud H, Ravard C, Claustrat F, et al. Xenoestrogen interaction with human sex hormone-binding globulin (hSHBG). Steroids 1999;64:328-34 (Pubitemid 29284333)
66. Kennelly EJ, Baggett S, Nuntanakorn P, et al. Analysis of thirteen populations of black cohosh for formononetin. Phytomedicine 2002;9:461-7 (Pubitemid 34920173)
67. Jiang B, Kronenberg F, Balick MJ, et al. Analysis of formo-nonetin from black cohosh (Actaea racemosa). Phytomedicine 2006;13:477-86 (Pubitemid 43922399)
68. Avula B, Wang YH, Smillie TJ, et al. Quantitative determination of triterpenoids and formononetin in rhizomes of black cohosh (Actaea racemosa) and dietary supplements by using UPLC-UV/ELS detection and identification by UPLC-MS. Planta Med 2009;75:381-6
69. Liske E, Hanggi W, Henneicke-von Zepelin H, et al. Physiological investigation of a unique extract of black cohosh (Cimicifugae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. J Womens Health Gend Based Med 2002;11:163-74
70. Burdette JE, Liu J, Chen S, et al. Black cohosh acts as a mixed competitive ligand and partial agonist of the serotonin receptor. J Agric Food Chem 2003;51:5661-70
71. Popp M, Schenk R, Abel G. Cultivation of Cimicifuga racemosa (L.) nuttal and quality of CR extract BNO 1055. Maturitas 2003;44:S1-7 (Pubitemid 36263030)
72. Lethaby A, Marjoribanks J, Kronenberg F, et al. Phytoestrogens for vasomotor menopausal symptoms. Cochrane Database Systematic Rev 2007, Issue 4. Art. No.: CD001395
73. Faure ED, Chantre P, Mares P. Effects of a standardized soy extract on hot flushes: a multicenter, double-blind, randomized, placebo-controlled study. Menopause 2002;9:329-34 (Pubitemid 36701892)
74. Bicca ML de O, Horta BL, Lethaby AE. Double-blind randomized clinical trial to assess the effectiveness of soy isoflavones in the relief of climacteric symptoms. Unpublished data, cited in Cochrane Database of Systematic Reviews 2007
75. Khaodhiar L, Ricciotti HA, Li L, et al. Daidzein-rich isoflavone aglycones are potentially effective in reducing hot flashes in menopausal women. Menopause 2008;15:125-32
76. Tice JA, Ettinger B, Ensrud K, et al. Phytoestrogen supplements for the treatment of hot flashes: the Isoflavone Clover Extract (ICE) study: a randomized controlled trial. JAMA 2003;290:207-14 (Pubitemid 37430059)
77. Baber RJ, Templeman C, Morton T, et al. Randomized placebo-controlled trial of an isoflavone supplement and menopausal symptoms in women. Climacteric 1999;2:85-92
78. Knight DC, Howes JB, Eden JA. The effect of Promensil, an isoflavone extract, on menopausal symptoms. Climacteric 1999; 2:79-84 (Pubitemid 29333646)
79. van de Weijer PH, Barentsen R. Isoflavones from red clover (Promensil) significantly reduce menopausal hot flush symptoms compared with placebo. Maturitas 2002;42:187-93 (Pubitemid 34876810)
80. Hidalgo LA, Chedraui PA, Morocho N, et al. The effect of red clover isoflavones on menopausal symptoms, lipids and vaginal cytology in menopausal women: a randomized, double blind, placebo-controlled study. Gynecol Endocrinol 2005;21:257-64 (Pubitemid 43041746)
81. Li Y, Liu K, Lei W, et al. Effect of soy isoflavones on peri-meno-pausal symptom and estrogen. Wei Sheng Yan Jiu 2010;39:56-9
82. Nahas EA, Nahas-Neto J, Orsatti FL, et al. Efficacy and safety of a soy isoflavone extract in postmenopausal women: a randomized, double-blind, and placebo-controlled study. Maturitas 2007;58:249-58 (Pubitemid 350103531)
83. Carmignani LO, Pedro AO, Costa Paiva LH, et al. The effect of dietary soy supplementation compared to estrogen and placebo on menopausal symptoms: a randomized controlled trial. Matu-ritas 2010;67:262-9
84. Chedraui P, San Miguel G, Schwager G. The effect of soy-derived isoflavones over hot flushes, menopausal symptoms and mood in climacteric women with increased body mass index. Gynecol Endocrinol 2011;27:307-13
85. del Giorno C, da Fonseca AM, Bagnoli VR, et al. Effects of Trifolium pratense on the climacteric and sexual symptoms in postmenopause women. Rev Assoc Med Bras 2010;56:558-62
86. Newton K, Reed S, LaCroix A, et al. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. Ann Intern Med 2006;145:869-79 (Pubitemid 351639962)
87. Geller SE, Shulman LP, van Breemen RB, et al. Safety and efficacy of Black cohosh and Red Clover for the management of vaso-motor symptoms: a randomized controlled trial. Menopause 2009;16:1156-66
88. Osmers R, Friede M, Liske E, et al. Efficacy and safety of isopro-panolic black cohosh extract for climacteric symptoms. Obstet Gynecol 2005;105:1074-83 (Pubitemid 40571028)
89. Wuttke W, Seidlova-Wuttke D, Gorkow C. The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. Maturitas 2003;44:S67-77 (Pubitemid 36263037)
90. Frei-Kleiner S, Schaffner W, Rahlfs V, et al. Cimicifuga racemosa dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial. Maturitas 2005;51: 397-404 (Pubitemid 41019367)
91. Nappi R, Malavasi B, Brundu B, et al. Efficacy of Cimicifuga racemosa on climacteric complaints: a randomized study versus low-dose transdermal estradiol. Gynecol Endocrinol 2005; 20:30-5 (Pubitemid 40445238)
92. Bai W, Henneicke-von Zepelin H, Wang S, et al. Efficacy and tolerability of a medicinal product containing an isopropanolic black cohosh extract in Chinese women with menopausal symptoms: a randomized, double blind, parallel-controlled study versus tibolone. Maturitas 2007;58:31-41 (Pubitemid 47268705)
93. Uebelhack R, Blohmer JU, Graubaum HJ, et al. Black cohosh and St. John' s wort for climacteric complaints: a randomized trial. Obstet Gynecol 2006;107:247-55
94. Liske E, Hanggi W, Henneicke-von Zepelin H, et al. Physiological investigation of a unique extract of black cohosh (Cimicifu-gae racemosae rhizoma): a 6-month clinical study demonstrates no systemic estrogenic effect. J Womens Health Gend Based Med 2002;11:163-74
95. Pockaj BA, Gallagher JG, Loprinzi CL, et al. Phase III double-blind, randomized, placebo-controlled crossover trial of black cohosh in the management of hot flashes: NCCTG Trial N01CC1. J Clin Oncol 2006;20:2836-41 (Pubitemid 46630583)
96. Verhoeven MO, van der Mooren MJ, van de Weijer PH, et al. Effect of a combination of isoflavones and Actaea racemosa Linnaeus on climacteric symptoms in healthy symptomatic per-imenopausal women: a 12-week randomized, placebo-controlled, double-blind study. Menopause 2005;12:412-20 (Pubitemid 41098654)
97. Aso T. Equol improves menopausal symptoms in Japanese women. J Nutr 2010;140:1386S-9S
98. Jou JH, Wu SC, Chang FW, et al. Effect of intestinal production of equol on menopausal symptoms in women treated with soy isoflavones. Int J Gynaecol Obstet 2008;102:44-9
99. Tempfer CB, Froese G, Heinze G, et al. Side effects of phytoes-trogens: a meta-analysis of randomized trials. Am J Med 2009; 122:939-46
100. Unfer V, Casini ML, Costabile L, et al. Endometrial effects of long-term treatment with phytoestrogens: a randomized double-blind placebo-controlled study. Fertil Steril 2004; 82:145-8 (Pubitemid 38968790)
101. Palacios S, Pornel B, Vásquez F, et al. Long-term endometrial and breast safety of a specific, standardized soy extract. Climacteric 2010;13:368-75
102. Ju YH. Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. J Nutr 2001;131:2957-62 (Pubitemid 33063130)
103. Ju YH, Doerge DR, Alfred CD, et al. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res 2002;62:2474-7 (Pubitemid 34462720)
104. Ju YH, Doerge DR, Woodling KA, et al. Dietary genistein negates the inhibitory effect of letrozole on the growth of aromatase-expressing estrogen-dependent human breast cancer cells (MCF-7Ca) in vivo. Carcinogenesis 2008;29:2162-8
105. Ruhlen RL, Haubner J, Tracy JK, et al. Black cohosh does not exert an estrogenic effect on the breast. Nutr Cancer 2007;59:269-77 (Pubitemid 350230744)
106. Davis VL, Jayo MJ, Ho A, et al. Black cohosh increases meta-static mammary cancer in transgenic mice expressing c-erbB2. Cancer Res 2008;68:8377-83
107. Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4 phenotypes. Clin Pharmacol Ther 2005;77:415-26 (Pubitemid 40719269)
108. Rockwell S, Liu Y, Higgins SA. Alteration of the effects of cancer therapy agents on breast cancer cells by the herbal medicine black cohosh. Breast Cancer Res Treat 2005;90:233-9 (Pubitemid 40576836)
109. Chow E C-Y, Teo M, Ring JA, et al. Liver failure associated with the use of black cohosh for menopausal symptoms. MJA 2008;188:420-2